EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

The SS18-SSX fusion oncoprotein: Friend and foe in targeted therapy for synovial sarcoma

Gavin M Anchondo, Kyra Parker, Alexis Bruce, Elizabeth Cortez, L E Su

Oncology Research · 2025 · 33 (5) · 1001-1005

DOI: 10.32604/or.2025.060573 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Oncology Research, 2025. Verfasst von Gavin M Anchondo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, Jacksonville State University, Jacksonville, AL 36265, USA. Hauptthemen laut MEDLINE: Sarcoma, Synovial, Oncogene Proteins, Fusion. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Synovial sarcoma is a high-grade soft tissue malignancy characterized by a unique fusion gene known as SS18-SSX. The SS18-SSX fusion protein acts as an oncogenic driver of synovial sarcoma, and it has thus been commonly accepted that disruption of SS18-SSX function represents a therapeutic means of treating synovial sarcoma, but emerging evidence suggests that upon depletion of SS18-SSX, an anti-apoptotic signal surprisingly arises to protect synovial sarcoma cell survival. In this article, we discuss the controversial roles of SS18-SSX's transcriptional activity in synovial sarcoma biology and outline a synergistic strategy for overcoming the resistance of synovial sarcoma cells to SS18-SSX targeted therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sarcoma, SynovialOncogene Proteins, FusionHumansMolecular Targeted TherapyAnimals

Stichwörter der Autor:innen

SS18-SSXSynovial sarcomaTargeted therapy

Substanzen

Oncogene Proteins, FusionSS18-SSX1 fusion protein

Autor:innen und Institutionen

  • Department of Biology, Jacksonville State University, Jacksonville, AL 36265, USA.

Zitieren

APA

Anchondo, G. M., Parker, K., Bruce, A., Cortez, E., & Su, L. E. (2025). The SS18-SSX fusion oncoprotein: Friend and foe in targeted therapy for synovial sarcoma. Oncology Research, 33(5), 1001-1005. https://doi.org/10.32604/or.2025.060573

Vancouver

Anchondo GM, Parker K, Bruce A, Cortez E, Su LE. The SS18-SSX fusion oncoprotein: Friend and foe in targeted therapy for synovial sarcoma. Oncology Research. 2025;33(5):1001-1005. doi:10.32604/or.2025.060573

BibTeX
@article{Anchondo2025,
  author = {Anchondo, Gavin M and Parker, Kyra and Bruce, Alexis and Cortez, Elizabeth and Su, L E},
  title = {The SS18-SSX fusion oncoprotein: Friend and foe in targeted therapy for synovial sarcoma},
  journal = {Oncology Research},
  year = {2025},
  volume = {33},
  number = {5},
  pages = {1001--1005},
  doi = {10.32604/or.2025.060573}
}
Kostenlos starten →